A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

The researchers are doing this study to find out whether obecabtagene autoleucel (obe-cel) is an effective treatment for people with B-cell acute lymphoblastic leukemia (ALL) that is in complete remission (CR, meaning all signs of cancer are gone) with no measurable residual disease (MRD-negative, meaning there are no detectable cancer cells). Participants in this study will have received past treatment for their B-cell ALL, and their disease will be in MRD-negative CR for the first time (first MRD-negative CR).

Trial Details

NCT ID
NCT07400029
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Obecabtagene Autoleucel
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Stanford, California, United States|37.42411,-122.16608
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292

Key Eligibility Criteria

  • Diagnosis of CD19+ B-cell ALL.
  • Both Ph-negative and Ph-positive are allowed
  • Patients with EMD must have detectable disease in the bone marrow (by flow cytometry or molecular methods) in order to follow MRD.
  • Patients aged ≥ 40 years at time of screening A.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →